BioCardia, Inc. (Nasdaq: BCDA), a leader in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, announced its financial results for the year ended December 31, 2025, in a press release dated March 24, 2026. The company reported a net loss of approximately $8.2 million for 2025, compared to a loss of $7.9 million in 2024. Notably, there were no revenues reported for 2025, a decrease from $58,000 in 2024, primarily due to the fulfillment of performance obligations for several business partners. Research and development expenses increased to approximately $5.0 million, reflecting the closeout activities in the CardiAMP Heart Failure Trial and the initiation of the CardiAMP Heart Failure II Trial. Selling, general, and administrative expenses decreased to approximately $3.3 million, down from $3.7 million in the previous year. The company ended the year with cash and cash equivalents totaling approximately $2.5 million. In addition to the financial results, BioCardia highlighted significant business developments, including advancements in the CardiAMP autologous cell therapy for ischemic heart failure and ongoing regulatory discussions with the FDA and Japan's PMDA. The company is actively enrolling patients in the CardiAMP HF II Trial across multiple sites and has received positive feedback from the PMDA regarding its clinical data. BioCardia plans to host a corporate update conference call to discuss these results and business highlights further.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.